patent.fyi
Applications  /  US 2026/0355319
United States Patent Application Publication

US 2026/0355319 A1

Published
Nov 12, 2026
Filed
Mar 19, 2026
Earliest date on the face
Apr 27, 2023
Classification
A61K 47/12
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Salicylic acid as the active

What ifWhat if salicylic acid supplied the acidic active?
Claim language“a long-chain alkyl dicarboxylic acid”

Dissolve salicylic acid, an aromatic monocarboxylic acid, in propylene glycol and blend the solution into a water-miscible carrier. Set the dilution ratio so the final salicylic acid concentration stays below its measured solubility at the final pH and storage temperature.

1.2Triethanolamine for partial neutralization

What ifWhat if triethanolamine provided the proton-accepting component?
Claim language“an amidoamine”

Blend azelaic acid with triethanolamine, a tertiary amino alcohol, in propylene glycol. Triethanolamine accepts protons from azelaic acid and forms ionic species that disperse into the aqueous carrier during dilution.

1.2Acid rich concentrate

What ifWhat if the acid-to-amidoamine mass ratio were 2:1?
Claim language“the ratio a:b is from 1:9 to 1:1”

Disperse two parts micronized azelaic acid in one part amidoamine to form a paste. Dilute the paste into a propylene glycol and water carrier at a loading below the measured azelaic acid solubility in the final carrier.

1.2Suspension of micronized acid

What ifWhat if dilution produced an opaque suspension of azelaic acid particles?
Claim language“a clear solution is formed”

Disperse micronized azelaic acid into an aqueous carrier containing prehydrated xanthan gum. The gum increases low-shear viscosity and slows settling, while mixing distributes the particles throughout the carrier.

1.2Dilution at mildly alkaline ph

What ifWhat if the diluted liquid had a pH of 7.5?
Claim language“a pH of less than 7”

Dilute the concentrate into water and add dilute sodium hydroxide under stirring until the measured pH reaches 7.5. At this pH, azelaic acid is predominantly present as dissolved azelate ions.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Dicarboxylic acid feed for textile trials

A textile laboratory uses a low-water sebacic acid and amidoamine concentrate to prepare acidic rinse baths for fabric coupon trials. A technician meters the concentrate into a stirred water tank and checks the diluted bath for clarity and a pH below 7 before adding the coupons. The technician holds bath temperature, immersion time, and liquor-to-fabric ratio constant across the trial series.

Component substitution

Diethanolamine as the neutralizing base

Diethanolamine replaces the amidoamine in a low-water adipic acid concentrate. A jacketed mixer receives adipic acid incrementally into stirred diethanolamine at an initial ratio of one mole of base per mole of diacid, forming an ammonium hydrogen adipate mixture. A dilution test measures pH and turbidity and checks for visible crystals after the sample returns to room temperature.

Parameter or scale variation

Batch dilution with a defined hold

A jacketed vessel receives 9.90 kg of deionized water at 35 °C and 0.10 kg of concentrate made with sebacic acid and amidoamine at a 1:6 mass ratio. A pitched-blade impeller mixes the batch for 15 minutes after dosing, and the jacket cools it to 22 °C. After a 24-hour hold at 22 °C, the operator checks the batch for clarity and visible precipitate and measures whether the pH is below 7.

Combination with existing systems

In-line dilution on a filling line

A positive-displacement pump feeds the low-water concentrate into a flowing hydrophilic carrier upstream of a static mixer. The mixer discharges to a small surge vessel that supplies a liquid bottle filler. A pH probe and an optical turbidity sensor downstream of the mixer control a divert valve, and the stream reaches the filler when the pH is below 7 and turbidity meets the established clarity limit.

Concentrate dosing into a hydrogel base

A stirred vessel hydrates hydroxyethyl cellulose in water to prepare a hydrophilic gel base. A separate premix vessel dilutes the low-water dodecanedioic acid and amidoamine concentrate in a reserved portion of the batch water, and an operator verifies clarity and a pH below 7 before transfer. A metering pump feeds the premix below the surface of the gel while an anchor impeller distributes it, and the finished gel is checked for pH and visible crystals.

Automated or data-driven variant

Automated screening of concentrate dilution

A benchtop dispensing system prepares batches of adipic acid and amidoamine at programmed mass ratios in capped vials and dispenses aliquots of each into a series of water dilutions. A temperature-controlled shaker mixes the vials, and an automated station records pH and turbidity after equilibration and again after a fixed hold. Software ranks the dilutions by dissolved-feed loading and flags samples with a pH of 7 or greater, turbidity above a calibrated limit, or visible sediment detected by a camera.

Specific version of a part

Micronized azelaic acid feed

Use azelaic acid, a nine-carbon dicarboxylic acid, with a median particle diameter of 10 micrometers. Add the powder gradually to the stirred amidoamine so the liquid wets the particles as they enter the blend.

Fatty acid derived amidoamine

Use oleamidopropyl dimethylamine as the amidoamine and blend it with azelaic acid at an acid-to-amidoamine mass ratio of 1:3. The terminal tertiary amine accepts a proton from a carboxyl group and forms an ammonium carboxylate.

Clear acidic aqueous dilution

Meter the concentrate into a stirred water and propylene glycol carrier and set the final pH to 5.5 with dilute citric acid. Set the concentrate loading below the measured azelaic acid solubility in that carrier at pH 5.5, then inspect the equilibrated liquid for haze and visible crystals.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0182054 A1
Published
Jul 16, 2009
Filed
Jan 8, 2009
Class
A61K 31/194
Document BUS 10,519,292 B2
Published
Dec 31, 2019
Filed
May 24, 2019
Class
C08J 11/16
Claim 1
Document A
Document B
1.1a. a long-chain alkyl dicarboxylic acid having poor water solubility and having six to twelve carbon atoms selected from the group consisting of adipic acid, azelaic acid, sebacic acid, and dodecanedioc acid; and
Examples of the suitable dicarboxylic acid are adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, and any suitable combinations thereof.
A · US 2009/0182054 A1 · ¶ 31
In some embodiments, the at least one organic acid is selected from the group consisting of succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, and combinations thereof.
B · US 10,519,292 B2 · ¶ 26
1.2b. an amidoamine wherein the ratio a:b is from 1:9 to 1:1, wherein upon adding the substantially-anhydrous, dermatologic concentrate to water or a hydrophilic carrier a clear solution is formed, having a pH of less than 7, that is visibly free of long-chain alkyl dicarboxylic acid precipitate.
Also suitable are the compounds that can form complexes with dicarboxylic acids. The complexing compounds in accordance with the present invention are compounds having at least one amide bond.
A · US 2009/0182054 A1 · ¶ 35

An empty cell means only that no passage was reproduced there.

Statements in these documents
There is a need for a safe and effective topical treatment of skin disorders associated with skin inflammation such as acne, rosacea, seborrheic dermatitis, perioral dermatitis, and facial dermatitis without disadvantages of the prior art.
A · US 2009/0182054 A1 · ¶ 10
In general, active ingredient in the solubilized form is more bioavailable than in the un-solubilized form.
A · US 2009/0182054 A1 · ¶ 7
These expensive methods pollute the environment and do not utilize the contaminated plastic waste materials that could be used as a raw feedstock for new products.
B · US 10,519,292 B2 · ¶ 5
Mechanical recycling is not economically viable because cleaning contaminated plastics or contaminated plastic waste requires intensive resources and labor.
B · US 10,519,292 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0355319 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355319/, SHA-256 dff8f961cd2a65c175587a0f2066448946b794f79c936451bf2090ee38975c7b
First published
Permanent addresshttps://patent.fyi/US20260355319/
Content fingerprint (SHA-256)dff8f961cd2a65c175587a0f2066448946b794f79c936451bf2090ee38975c7b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi